Medicine
Dihydroergotamine 4 mg/mL nasal spray
Dihydroergotamine 4 mg/mL nasal spray is a generic prescription medicine for nasal use, made by 6 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not refrigerate or freeze. Store below 25°C (77°F).
Key facts
- Active ingredient (INN)
- Dihydroergotamine
- Brand
- Sold under the generic name
- Strength
- 4 mg/mL
- Dosage form
- Nasal spray
- Route
- Nasal
- Packs
- 8 vials, 1 vial, 8 kits and 5 more
- Manufacturers
- CiplaIndiaAdvagen PharmaHikma PharmaceuticalsOceanside PharmaceuticalsSomerset TherapeuticsTrifluent Pharma
- Origin register
- US FDA, United States
- Storage
- Do not refrigerate or freeze. Store below 25°C (77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N02CA01 Dihydroergotamine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 18 March 2013
- Identifiers
- RxCUI 861668DailyMed set ID 65f8c60d-9213-48ac-8233-acc5d44548f4, 1ecb2311-eee3-4230-a019-a3496308cff1, 9ffe6d5a-7348-0498-e053-2a95a90a97a8 +3NDC 72888-096, 69097-503, 24201-463 +3Application ANDA216881, ANDA212907, ANDA211393 +2
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 8 vial in 1 kit / 1 mL in 1 vial | 69097-503-27 | CiplaIndia | 23 May 2020 |
| 1 vial in 1 kit / 1 mL in 1 vial | 69097-503-31 | CiplaIndia | 23 May 2020 |
| 8 kit in 1 kit / 1 vial, glass in 1 kit / 1 mL in 1 vial, glass | 72888-096-19 | Advagen Pharma | 23 June 2023 |
| 1 vial, glass in 1 kit / 1 mL in 1 vial, glass | 72888-096-34 | Advagen Pharma | 23 June 2023 |
| 8 vial in 1 carton / 1 mL in 1 vial | 24201-463-08 | Hikma Pharmaceuticals | 14 April 2020 |
| 8 vial in 1 kit / 1 mL in 1 vial | 68682-357-10 | Oceanside Pharmaceuticals | 18 March 2013 |
| 8 carton in 1 kit / 1 vial in 1 carton / 1 mL in 1 vial | 70069-880-08 | Somerset Therapeutics | 24 March 2026 |
| 8 kit in 1 kit / 1 vial, glass in 1 kit / 1 mL in 1 vial, glass | 73352-096-19 | Trifluent Pharma | 8 July 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 12 April 1946 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Dihydroergotamine 4 mg/mL nasal spray.
Other strengths and forms of Dihydroergotamine
Clinical summary
Dihydroergotamine is an ergotamine derivative indicated for the acute treatment of migraine headaches with or without aura. It is available as injection, nasal spray and powder for subcutaneous and intramuscular use. MedsAcross supplies Dihydroergotamine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DihydroergotamineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Dihydroergotamine Mesylate prescribing information (Oceanside Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Dihydroergotamine 4 mg/mL nasal spray for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.